Teva to host conference call on february 24, 2025 to discuss new data presented for duvakitug (anti-tl1a) positive phase 2b results at the 20th annual congress of the european crohn's and colitis organisation (ecco)

Tel aviv, israel, feb. 18, 2025 (globe newswire) -- teva pharmaceutical industries ltd. (nyse and tase: teva) announced today that it will conduct a conference call and live webcast at 8 am e.t. on monday, february 24, 2025. during the conference call, eric hughes, md, phd, executive vice president of global r&d and chief medical officer, and external ibd key opinion leaders (kols) will discuss new data presented for duvakitug (anti-tl1a) positive phase 2b results at the 20th annual congress of the european crohn's and colitis organization (ecco).
TEVA Ratings Summary
TEVA Quant Ranking